ZA201007722B - Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor - Google Patents

Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor

Info

Publication number
ZA201007722B
ZA201007722B ZA2010/07722A ZA201007722A ZA201007722B ZA 201007722 B ZA201007722 B ZA 201007722B ZA 2010/07722 A ZA2010/07722 A ZA 2010/07722A ZA 201007722 A ZA201007722 A ZA 201007722A ZA 201007722 B ZA201007722 B ZA 201007722B
Authority
ZA
South Africa
Prior art keywords
inhibitor
cmet
treating cancer
erbb
axl
Prior art date
Application number
ZA2010/07722A
Other languages
English (en)
Inventor
Tona Morgan Gilmer
James G Greger
Li Liu
Hong Shi
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41257222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201007722(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of ZA201007722B publication Critical patent/ZA201007722B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2010/07722A 2008-05-05 2010-10-28 Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor ZA201007722B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5032208P 2008-05-05 2008-05-05
PCT/US2009/042768 WO2009137429A1 (en) 2008-05-05 2009-05-05 Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor

Publications (1)

Publication Number Publication Date
ZA201007722B true ZA201007722B (en) 2011-08-31

Family

ID=41257222

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/07722A ZA201007722B (en) 2008-05-05 2010-10-28 Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor

Country Status (19)

Country Link
US (3) US20090274693A1 (OSRAM)
EP (1) EP2274304A4 (OSRAM)
JP (1) JP2011519941A (OSRAM)
KR (1) KR20110004462A (OSRAM)
CN (1) CN102083824A (OSRAM)
AR (1) AR071631A1 (OSRAM)
AU (1) AU2009244453B2 (OSRAM)
BR (1) BRPI0912582A2 (OSRAM)
CA (1) CA2723699A1 (OSRAM)
CL (1) CL2009001063A1 (OSRAM)
EA (1) EA020779B1 (OSRAM)
IL (1) IL209057A0 (OSRAM)
MX (1) MX2010012101A (OSRAM)
PE (1) PE20091832A1 (OSRAM)
SG (1) SG190623A1 (OSRAM)
TW (1) TW201006829A (OSRAM)
UY (1) UY31800A (OSRAM)
WO (1) WO2009137429A1 (OSRAM)
ZA (1) ZA201007722B (OSRAM)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
PT2387563E (pt) 2009-01-16 2013-03-25 Exelixis Inc Sal de malato de n-(4-{[6,7-bis(metiloxi)quinolin-4- il]oxi}fenil)-n¿-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, e suas formas cristalinas para o tratamento de cancro
PE20120553A1 (es) 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
SI2451445T1 (sl) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
AR077595A1 (es) * 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
WO2011014872A2 (en) * 2009-07-31 2011-02-03 The Johns Hopkins University Compositions and methods for diagnosing, treating or preventing neoplasias
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
PL2719708T3 (pl) * 2009-11-13 2018-04-30 Daiichi Sankyo Europe Gmbh Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3
HUE057184T2 (hu) 2010-07-16 2022-04-28 Exelixis Inc C-MET modulátor gyógyszerészeti készítmények
PH12013500333A1 (en) 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN103402505A (zh) 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
MX2013007429A (es) * 2010-12-23 2014-01-31 Nestec Sa Seleccion de farmacos para terapia de cancer maligno usando disposiciones a base de anticuerpos.
CN102532109B (zh) * 2010-12-27 2015-05-13 浙江海正药业股份有限公司 一种拉帕替尼及其盐的合成方法
CN102093421B (zh) * 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
KR102030447B1 (ko) 2011-02-10 2019-11-08 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) * 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
IN2014CN02971A (OSRAM) 2011-10-20 2015-07-03 Exelixis Inc
CN103958497B (zh) 2011-11-14 2017-09-01 亚尼塔公司 作为AXL和c‑MET激酶抑制剂的尿嘧啶衍生物
ES2758433T3 (es) * 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
SI2810937T1 (sl) 2012-01-31 2017-01-31 Daiichi Sankyo Company, Limited Derivat piridona
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
CN103664879A (zh) * 2012-09-17 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103705521A (zh) * 2012-09-28 2014-04-09 韩冰 一类治疗脑梗塞的化合物及其用途
WO2014093750A1 (en) * 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
EP2970126B1 (en) 2013-03-15 2019-03-06 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
WO2014165786A1 (en) 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
BR112016008125B1 (pt) 2013-10-14 2023-11-21 Janssen Biotech, Inc. Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
CN113425727A (zh) 2014-02-04 2021-09-24 安斯泰来制药株式会社 以二氨基杂环甲酰胺化合物为有效成分的医药组合物
AU2015218236B2 (en) 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
CN106456752B (zh) * 2014-04-03 2020-11-20 默克专利股份公司 癌症治疗剂的组合
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
WO2016019285A1 (en) 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
KR102634247B1 (ko) 2014-08-05 2024-02-05 엑셀리시스, 인코포레이티드 다발성 골수종을 치료하기 위한 약물 병용물
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
SG11201811062XA (en) 2016-06-21 2019-01-30 Janssen Biotech Inc Cysteine engineered fibronectin type iii domain binding molecules
CN110437145A (zh) * 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CN107235897B (zh) * 2016-09-27 2019-08-16 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
BR112019012154A2 (pt) 2016-12-14 2019-11-12 Janssen Biotech Inc domínios do tipo iii da fibronectina de ligação a cd8a
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
JP6605763B2 (ja) 2017-01-26 2019-11-13 小野薬品工業株式会社 キノリン誘導体のエタンスルホン酸塩
FI3583943T3 (fi) 2017-02-15 2024-10-29 Taiho Pharmaceutical Co Ltd Farmaseuttinen koostumus
WO2019049956A1 (ja) 2017-09-08 2019-03-14 大鵬薬品工業株式会社 抗腫瘍剤及び抗腫瘍効果増強剤
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
EP3914356A1 (en) * 2019-01-25 2021-12-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
CN115073367A (zh) * 2021-03-16 2022-09-20 南京科默生物医药有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
EP4323008A1 (en) 2021-04-14 2024-02-21 ARO Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236481T3 (es) * 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
EP2392565B1 (en) * 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
ITRM20030475A1 (it) * 2003-10-15 2005-04-16 Sipa Societa Industrializzazione P Rogettazione E Impianto e metodo per il condizionamento termico di oggetti
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP3168234A1 (en) * 2005-12-15 2017-05-17 Medimmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
US20080058312A1 (en) * 2006-01-11 2008-03-06 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
AU2007334402B2 (en) * 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
AU2008239594B2 (en) * 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
BRPI0721707A2 (pt) * 2007-05-17 2013-01-15 Genentech Inc estruturas de cristal de fragmentos de neuropilina e complexos de neuropilina-anticorpo
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CA2736563C (en) * 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors

Also Published As

Publication number Publication date
US20090274693A1 (en) 2009-11-05
US20130142790A1 (en) 2013-06-06
KR20110004462A (ko) 2011-01-13
CN102083824A (zh) 2011-06-01
US20130150363A1 (en) 2013-06-13
EA201071268A1 (ru) 2011-06-30
AR071631A1 (es) 2010-06-30
SG190623A1 (en) 2013-06-28
EA020779B1 (ru) 2015-01-30
EP2274304A4 (en) 2012-05-30
WO2009137429A1 (en) 2009-11-12
PE20091832A1 (es) 2009-12-25
JP2011519941A (ja) 2011-07-14
CA2723699A1 (en) 2009-11-12
BRPI0912582A2 (pt) 2015-07-28
AU2009244453B2 (en) 2012-07-19
AU2009244453A1 (en) 2009-11-12
EP2274304A1 (en) 2011-01-19
IL209057A0 (en) 2011-01-31
MX2010012101A (es) 2010-11-30
CL2009001063A1 (es) 2010-09-24
TW201006829A (en) 2010-02-16
UY31800A (es) 2009-11-10

Similar Documents

Publication Publication Date Title
IL209057A0 (en) Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor
IL216140A0 (en) Egfr inhibitors and methods of treating disorders
EP2358463A4 (en) INDIRECT AND DIRECT METHOD FOR THE SEQUESTRATION OF POLLUTANTS
IL212826A0 (en) Ingestible therapy activator system and method
EP2375903A4 (en) METHOD FOR TREATING SILENTNESS
PL2135664T3 (pl) Sposób obróbki spalin
IL195768A0 (en) Method of treating diseases with parp inhibitors
EP2318406A4 (en) THIOSEMICARBAZONHERMAL COMPOUNDS AND CANCER TREATMENT PROCEDURES
SI2271626T1 (sl) Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina
GB0819280D0 (en) Imgaing and radiotherapy methods
GB2462723B (en) An antenna and a method of manufacturing an antenna
EP2243725A4 (en) PACKAGING AND METHOD FOR THE PRODUCTION THEREOF
EP2350641A4 (en) Methods of Treatment
ZA201003301B (en) Mining machine and method of mining
WO2011097166A9 (en) Combination therapy for treating cancer comprising an igf-1r inhibitor and an hdac inhibitor
ZA201102410B (en) Package and method of formation
EP2335950A4 (en) TIRE DESIGN METHOD, AND TIRE THUS OBTAINED
EP2326535A4 (en) INFLATABLE SAFETY CUSHION AND METHOD OF FORMING AN INFLATABLE SAFETY CUSHION
IL218230A0 (en) Method of treating cancer
EP2348858A4 (en) PROCESS FOR THE TREATMENT OF THROMBOCYTOPENIA
IL203599A (en) Mark @ for treatment @ inhibitor @ of @ egfr
EP2003208A4 (en) PROCESS FOR THE PREPARATION OF ACRYLAMIDE
HK1162871A (en) A method of treating insomnia
GB0800556D0 (en) Method of treatment and treatment therefor
GB0806503D0 (en) Vehicle and method of modification thereof